These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Stellon AJ, Davies A, Compston J, Williams R. Gastroenterology; 1985 Nov 09; 89(5):1078-83. PubMed ID: 4043665 [Abstract] [Full Text] [Related]
74. Management of corticosteroid-induced osteoporosis: a clinician's perspective. Silverman SL. Calcif Tissue Int; 1992 Feb 09; 50(2):101-3. PubMed ID: 1571823 [No Abstract] [Full Text] [Related]
75. Understanding and Managing Corticosteroid-Induced Osteoporosis. Kobza AO, Herman D, Papaioannou A, Lau AN, Adachi JD. Open Access Rheumatol; 2021 Feb 09; 13():177-190. PubMed ID: 34239333 [Abstract] [Full Text] [Related]
76. Perceptions of pharmacists about adverse effects of corticosteroid therapy: focus on osteoporosis. Hudson JQ, Small RE, Buckley L. J Am Pharm Assoc (Wash); 1998 Feb 09; 38(6):710-6. PubMed ID: 9861789 [Abstract] [Full Text] [Related]
77. Osteoporosis prophylaxis during corticosteroid treatment. Chattopadhyay I, Showkathali AR, Jain AK. Postgrad Med J; 2002 Sep 09; 78(923):572. PubMed ID: 12357030 [No Abstract] [Full Text] [Related]
78. How do we manage specific types of osteoporosis? Sambrook PN, Naganathan V. Baillieres Clin Rheumatol; 1997 Aug 09; 11(3):597-612. PubMed ID: 9367039 [Abstract] [Full Text] [Related]
79. Current management of corticosteroid-induced osteoporosis: variations in awareness and management. Ryan JG, Morgan RK, Lavin PJ, Murray FE, O'Connell PG. Ir J Med Sci; 2004 Aug 09; 173(1):20-2. PubMed ID: 15732231 [Abstract] [Full Text] [Related]